Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Sep 2001HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCERis corrected byOUTCOME OF LOCALIZED PROSTATE CANCER MICHAEL J. ZELEFSKY, ZVI FUKS, MARGIE HUNT, HENRY J. LEE, DANNA LOMBARDI, CLIFTON C. LING, VICTOR E. REUTER, E.S. VENKATRAMAN, and STEVEN A. LEIBEL MICHAEL J. ZELEFSKYMICHAEL J. ZELEFSKY , ZVI FUKSZVI FUKS , MARGIE HUNTMARGIE HUNT , HENRY J. LEEHENRY J. LEE , DANNA LOMBARDIDANNA LOMBARDI , CLIFTON C. LINGCLIFTON C. LING , VICTOR E. REUTERVICTOR E. REUTER , E.S. VENKATRAMANE.S. VENKATRAMAN , and STEVEN A. LEIBELSTEVEN A. LEIBEL View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65855-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We present the long-term outcome and tolerance of 3-dimensional (D) conformal and intensity modulated radiation therapy for localized prostate cancer. Materials and Methods: Between October 1988 and December 1998, 1,100 patients with clinical stages T1c-T3 prostate cancer were treated with 3-D conformal or intensity modulated radiation therapy. Patients were categorized into prognostic risk groups based on pretreatment prostate specific antigen (PSA), Gleason score and clinical stage. Sextant biopsies were performed 2.5 years or greater after treatment to assess local control. PSA relapse was defined according to the consensus guidelines of the American Society for Therapeutic Radiation Oncology. Late toxicity was classified according to the Radiation Therapy Oncology Group morbidity grading scale. Median followup was 60 months. Results: At 5 years the PSA relapse-free survival rate in patients at favorable, intermediate and unfavorable risk was 85% (95% confidence interval [CI] ± 4), 58% (95% CI ± 6) and 38% (95% CI ± 6), respectively (p 4–20 ng/ml. Int J Radiat Oncol Biol Phys1997; 37: 1053. Google Scholar 32 : Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys2000; 46: 823. Google Scholar 33 : Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer. J Clin Oncol2000; 18: 3904. Google Scholar 34 : Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1–T3 adenocarcinoma of the prostate. Urology2000; 55: 85. Google Scholar 35 : Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997; 337: 295. Google Scholar 36 : Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol1997; 15: 1013. Google Scholar 37 : Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys2000; 47: 103. Google Scholar 38 : Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys2000; 48: 635. Google Scholar From the Departments of Radiation Oncology, Medical Physics, Pathology and Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByMahal B, O'Leary M and Nguyen P (2018) Hydrogel Spacing for Radiotherapy of Prostate Cancer: A Review of the LiteratureUrology Practice, VOL. 1, NO. 2, (79-85), Online publication date: 1-Jul-2014.Stone N, Stone M, Rosenstein B, Unger P and Stock R (2018) Influence of Pretreatment and Treatment Factors on Intermediate to Long-Term Outcome After Prostate BrachytherapyJournal of Urology, VOL. 185, NO. 2, (495-500), Online publication date: 1-Feb-2011.Kapoor D, Zimberg S, Ohrin L, Underwood W and Olsson C (2018) Utilization Trends in Prostate Cancer TherapyJournal of Urology, VOL. 186, NO. 3, (860-864), Online publication date: 1-Sep-2011.Stone N, Stock R, White I and Unger P (2018) Patterns of Local Failure Following Prostate BrachytherapyJournal of Urology, VOL. 177, NO. 5, (1759-1764), Online publication date: 1-May-2007.Zelefsky M, Chan H, Hunt M, Yamada Y, Shippy A and Amols H (2018) Long-Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate CancerJournal of Urology, VOL. 176, NO. 4, (1415-1419), Online publication date: 1-Oct-2006.TOUMA N, IZAWA J and CHIN J (2018) CURRENT STATUS OF LOCAL SALVAGE THERAPIES FOLLOWING RADIATION FAILURE FOR PROSTATE CANCERJournal of Urology, VOL. 173, NO. 2, (373-379), Online publication date: 1-Feb-2005.ZIETMAN A, CHUNG C, COEN J and SHIPLEY W (2018) 10-Year Outcome for Men With Localized Prostate Cancer Treated With External Radiation Therapy:: Results of a Cohort StudyJournal of Urology, VOL. 171, NO. 1, (210-214), Online publication date: 1-Jan-2004.POLLACK A, HANLON A, HORWITZ E, FEIGENBERG S, UZZO R and HANKS G (2018) Prostate Cancer Radiotherapy Dose Response: An Update of the Fox Chase ExperienceJournal of Urology, VOL. 171, NO. 3, (1132-1136), Online publication date: 1-Mar-2004.KOH H, KATTAN M, SCARDINO P, SUYAMA K, MARU N, SLAWIN K, WHEELER T and OHORI M (2018) A Nomogram to Predict Seminal Vesicle Invasion by the Extent and Location of Cancer in Systematic Biopsy ResultsJournal of Urology, VOL. 170, NO. 4 Part 1, (1203-1208), Online publication date: 1-Oct-2003.ZELEFSKY M, MARION C, FUKS Z and LEIBEL S (2018) Improved Biochemical Disease-Free Survival of Men Younger Than 60 Years With Prostate Cancer Treated With High Dose Conformal External Beam RadiotherapyJournal of Urology, VOL. 170, NO. 5, (1828-1832), Online publication date: 1-Nov-2003.Related articlesJournal of UrologyNov 9, 2018, 11:31:10 AMOUTCOME OF LOCALIZED PROSTATE CANCER Volume 166Issue 3September 2001Page: 876-881 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsradiation dosageprostatic neoplasmsradiotherapy, conformalriskprostateMetricsAuthor Information MICHAEL J. ZELEFSKY More articles by this author ZVI FUKS More articles by this author MARGIE HUNT More articles by this author HENRY J. LEE More articles by this author DANNA LOMBARDI More articles by this author CLIFTON C. LING More articles by this author VICTOR E. REUTER More articles by this author E.S. VENKATRAMAN More articles by this author STEVEN A. LEIBEL More articles by this author Expand All Advertisement PDF DownloadLoading ...